Adicet Bio

ACET Rare disease Lead: Phase 1 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-12

Catalyst timeline

Prula-cel Ph1 interim3Q 2026Prula-cel Ph1 interim, 3Q 2026, major
Prula-cel filing3Q 2026Prula-cel filing, 3Q 2026, material
Prula-cel interim2H 2026Prula-cel interim, 2H 2026, material
Prula-cel RA Ph1 interim2H 2026Prula-cel RA Ph1 interim, 2H 2026, material
ADI-212 IND filing3Q 2026ADI-212 IND filing, 3Q 2026, notable
Prula-cel / pivotal program start2H 2026Prula-cel / pivotal program start, 2H 2026, notable
in vivo CAR-T platform readout2H 2026in vivo CAR-T platform readout, 2H 2026, notable
ADI-212 trial start4Q 2026ADI-212 trial start, 4Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

prula-cel

prulacabtagene leucel · ADI-001

Cell Target: CD20

Lupus Nephritis Phase 1 NCT06375993
Systemic Lupus Erythematosus Phase 1 NCT06375993
Systemic Sclerosis Phase 1 NCT06375993
Idiopathic Inflammatory Myopathies Phase 1 NCT06375993
Stiff Person Syndrome Phase 1 NCT06375993
Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis Phase 1
Rheumatoid Arthritis Phase 1 NCT07100873

ADI-212

Cell Target: PSMA

Metastatic Castration-Resistant Prostate Cancer Preclinical CRISPR Therapeutics

Discontinued (1)

ADI-270 — Clear Cell Renal Cell Carcinoma · strategic reprioritization of pipeline to optimize development of assets

Biotech Distilled coverage (1)

2026-08-07 Adicet Bio (ACET) — Scientific Deep Dive for Prula-cel, ADI-212 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.